Hospira Names Svend Andersen to Lead Europe, Middle East and Africa

LEAMINGTON SPA, England, October 4, 2010 - Hospira (NYSE: HSP), a global specialty pharmaceutical and medication
delivery company, announced today that Svend Andersen has been named
corporate vice president and president, Europe, Middle East and Africa
(EMEA). In this capacity, he will be responsible for developing strategy,
delivering growth and attaining market leadership in the EMEA region.
Andersen, 48, will report to Ron Squarer, senior vice president and chief
commercial officer, effective Nov. 1, 2010.

"Svend is an accomplished, dynamic and ambitious business leader who
brings global experience in driving profitable growth and creating value
within the generics and branded pharmaceuticals spaces," Squarer said. "In
his more than 20 years in the healthcare industry, he has compiled a strong
track record of introducing new products, developing markets and building
teams, all of which will be essential as Hospira takes on new opportunities
and grows its current business in the EMEA."

Under Andersen's leadership, Hospira will advance its EMEA strategy,
which includes expanding the company's geographic footprint, growing its
leading position in generic injectable pharmaceuticals and biosimilars, and
increasing market share in infusion devices and consumables. Sales in the
EMEA comprised 14 percent of Hospira's total sales in 2009.

Most recently, Andersen served as executive vice president, Western
Europe, at Actavis, the world's fifth largest generic specialty
pharmaceutical company. There, he drove significant growth in the company's
hospital business, led five acquisitions, opened subsidiaries in six European
countries and, in 2009, launched over 300 products and brands. He led the
regional expansion from eight to 15 markets, and bolstered the company's
positions in the United Kingdom, Germany, Benelux and the Nordic countries.
He also was responsible for commercial operations, finance, supply,
regulatory and business development, with oversight of legal and intellectual
property.

Prior to joining Actavis, Andersen was vice president, general manager at
Alpharma, a global specialty pharmaceutical company, where he directed
strategy, restructured the organisation and revitalised the business prior to
its acquisition by Actavis. He has also served as vice president, commercial
operations, at Ferrosan, a consumer healthcare and medical devices company,
and worked as a business consultant to four start-up companies.

Andersen earned his Bachelor of Science in Economic Sciences and degrees
in International Marketing; Organisational Behaviours and Strategic Planning;
and Advanced Advertising, all at Copenhagen Business School.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM). As the world leader in
specialty generic injectable pharmaceuticals, Hospira offers one of the
broadest portfolios of generic acute-care and oncology injectables, as well
as integrated infusion therapy and medication management solutions. Through
its products, Hospira helps improve the safety, cost and productivity of
patient care. The company is headquartered in Lake Forest, Ill., and has more
than 13,500 employees. The head office for Hospira in Europe, Middle East and
Africa is in Leamington Spa, UK. Learn more at www.hospira.com.

Media (Europe), Athena, Hannah Stacey, +44-(0)208-956-2289, or Media (U.S.), Dan Rosenberg, +1-224-212-3366, or Financial Community, Karen King, +1-224-212-2711, all of Hospira. PHOTO: photos.prnewswire.com/prnh/20040503/HSPLOGO; www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO